|
Further reading from Invested Early:
Hello.
Welcome back to Invested Early.
A clinical-stage biotech just got acquired for $2.2 billion, sending shares up 40% in a single session. Circle scooped up nearly 1,000 blockchain patents from IBM. Semiconductor stocks extended their slide while oil crashed 8.7% after the U.S. and Iran paused hostilities.
Here's what's inside today:
🔍 Alternative data signals: what actually moves before the stock does
💊 The $2.2 billion biotech acquisition that closed the arbitrage window in hours
📲 Get alerts when stocks spike in popularity, insider activity, or sentiment
📈 Top gainers (and biggest losers) yesterday
This is not financial advice. Always do your own research. Past performance doesn't guarantee future results.
Alternative Data Signals (What Actually Moves First)
Earnings reports are lagging indicators. By the time you read about a company's growth, the stock has already priced it in. The investors who consistently find small caps before they run are looking at different data entirely.
Insider buying is the clearest. When executives spend their own money, they're making a statement. A CEO buying $500,000 of stock at the open market isn't doing it for optics.
Social sentiment shows momentum before price does. Reddit mentions, X chatter, YouTube watchlists: they reveal where attention is flowing before it translates into volume. The GameStop run showed up in Reddit data months before the stock went parabolic.
Hiring trends are forward-looking. A company posting 50 new engineering roles on LinkedIn isn't doing that because business is slowing down.
Insider buying clusters: high conviction, short delay
Social sentiment spikes: momentum signal, often noisy
Hiring trends: slower-moving, higher reliability
Web traffic surges: useful for consumer-facing companies
None of these work in isolation, the edge comes from combining them.
The $2.2 Billion Biotech That Just Got Bought
Forte Biosciences (FBRX) closed Monday at $76.56 because it's getting acquired for $77 a share in cash.
The news: Argenx (ARGX), a Dutch immunology company, agreed to acquire Forte in an all-cash deal valued at $2.2 billion. The deal is expected to close in Q3 2026.
Why it matters: Argenx isn't buying Forte for its revenue (there isn't any). It's paying $2.2 billion for FB102, a first-in-class anti-CD122 monoclonal antibody that selectively targets pathogenic T-cell and NK-cell activity. FB102 has shown promising Phase 1b results in vitiligo and celiac disease, with Phase 2 readouts expected later this year.
The honest risk: There isn't much. The acquisition is fully funded with no financing contingency. Shareholders will receive $77 per share. For investors who owned Forte before the announcement, the trade is complete. For everyone else, chasing the 44-cent spread isn't worth the wait.
The real lesson is what came before: Forte was trading at $21 in January. The 40% pop was the exit, not the entry.
Get Alerts Before the Move
Our partners at AltIndex built Real-Time Stock Alerts that notify you when a company spikes in popularity, insider activity, or sentiment.
Set up alerts for your watchlist and AltIndex monitors automatically. Reddit mentions surging? You'll know. Unusual insider buying? Flagged. The platform tracks social sentiment, job postings, app downloads, and more, then pushes notifications the moment something changes.
🎢 The Small-Cap Scoreboard
Here's where yesterday's biggest moves landed.
🟢 Yesterday’s biggest gainers
Symbol | Company | Price | Change | Market Cap | 52-Wk |
|---|---|---|---|---|---|
Baiya International | $8.12 | +116.0% | $42M | +131% | |
Forte Biosciences | $76.56 | +39.8% | $2.0B | +265% | |
Bitdeer Technologies | $14.87 | +11.2% | $1.8B | +89% | |
SiTime Corporation | $187.42 | +8.7% | $4.3B | +52% | |
ImmunityBio | $3.24 | +6.8% | $1.6B | -42% |
🔴 Yesterday’s biggest losers
Symbol | Company | Price | Change | Market Cap | 52-Wk |
|---|---|---|---|---|---|
Core Scientific | $11.23 | -9.1% | $4.2B | +186% | |
Cipher Mining | $4.52 | -8.0% | $1.5B | +98% | |
Hut 8 Corp | $17.89 | -6.2% | $2.4B | +112% | |
Riot Platforms | $12.43 | -5.1% | $4.1B | +21% | |
CleanSpark | $11.87 | -4.2% | $3.0B | +42% |
Two different stories. On the gainer side, Forte's acquisition dominated headlines while Circle's patent grab lifted crypto sentiment. Baiya's 116% spike was pure volatility.
The loser side was bitcoin miners. Miners with AI exposure got hit hardest as semiconductor stocks slid. Core Scientific led the decline at -9%, with Cipher and Hut 8 close behind.
(Data: Yahoo Finance.)
🫡 See You Soon
A $2.2 billion biotech buyout, a stablecoin company becoming America's largest blockchain patent holder, and bitcoin miners selling off while crypto treasury plays rallied. We'll keep showing you both sides.
Watching a name we should cover? Hit reply and tell us.
Cheers,
— Brandon & Blake of Invested Inc.
What did you think of today's edition?
ADVERTISING DISCLOSURES: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) This email is a paid advertisement by Interactive Offers and does not constitute investment advice. Invested Inc. has been compensated $5,000 by Interactive Offers for the distribution of this profile and related marketing materials. We have not performed due diligence on the company and the information provided is for informational purposes only. We are not a registered investment advisor or broker-dealer.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
The information provided in Invested Early is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. Stocks & Income is not a registered investment advisor, broker-dealer, or licensed financial planner. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We may hold positions in or receive compensation from the companies or products mentioned. Disclosures will be made where applicable.
Invested Early, Stocks & Income, AltIndex, Finance Wrapped, The Chain, and Future Funders are all owned by Invested, Inc.